Novavax and the others, the 5 vaccines approved by the EMA

• Use: safe vaccines for children.

  In Italy 15 thousand doses are administered in one day

• Magrini (Aifa): "Two new vaccines against Covid available from the beginning of 2022"

• Covid, Omicron is scary: Italy towards Christmas close.

  More and more regions in 'yellow'

• Omicron, Rasi: "Orange zone? We're getting closer"

Share

December 20, 2021 It is the latest addition to the vaccines approved in the EU, and joins Pfizer-BioNTech, Moderna, AstraZeneca and Johnson & Johnson.

The basic principle of the Novavax vaccine uses recombinant proteins, different from those with mRna (Pfizer / Biontech and Moderna) and with respect to those with viral vector (Astrazeneca and Johnson & Johnson). The drug uses pathogen proteins - antigens - to stimulate the immune system. 

The technique has been in use for some decades on other diseases: meningitis, hepatitis b and papilloma virus: it has been tested on over 45,000 people, demonstrating - according to what documents pharmaceutical company - a

Comirnaty, the Pfizer-Biontech vaccine, was the first to be authorized for use in Europe on December 21, 2020.

It is

starting 7 days after the second dose. It is administered through two injections, at least 21 days apart and should be stored in the freezer at a temperature between -90 ° C and -60 ° C.

It contains a molecule called messenger Rna (mRna) with instructions for making a protein found on Sars-CoV-2, the virus responsible for Covid-19.

Spikevax, the Moderna serum, like the previous one, is a messenger Rna. It was authorized by the EMA on January 6, 2021 and has a

from 14 days after the administration of the second dose, which is injected 28 days after the first. It is stored in the freezer at a temperature between -25 ° C and -15 ° C and is stable between + 2 ° C and + 8 ° C for 30 days.

Vaxzevria, AstraZeneca's serum, authorized on January 30, 2021, unlike the previous two, is a viral vector vaccine, which uses a modified version of the chimpanzee's adenovirus - no longer able to replicate - as a vector to deliver instructions for the synthesis of Sars-CoV-2 "spike protein". It has an

15 days after the second dose (when this is injected) between 10 and 12 weeks after the first and - from the data released immediately after the trial - it has a coverage that is close to 100% on the most serious cases of the disease. It is stored in the refrigerator at a temperature between 2 ° C and 8 ° C.

Janssen of the Janssen vaccine (Johnson & Johnson) uses a human adenovirus (Ad26) as a viral vector. It is given in a single dose from 18 years of age. (With circular 21 April 2021, the ministry recommends a preferential use of the vaccine in people over the age of 60). It was authorized in Italy on March 12, 2021 and is

% after 14 days from administration and 85% after 28 days from administration.

It is stored in the freezer at a temperature between -25 ° C and -15 ° C.

It usually takes five to ten years to develop a vaccine.

For Sars-CoV-2, on the other hand, in less than a year we have gone from the discovery of the previously unknown pathogen, to the beginning of vaccinations, inaugurated in Europe from the Vax-day of December 27, 2020.